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Introduction: Personalized treatment for patients with membranous nephropathy requires accurate
prediction of the disease course at an early stage. In this study, we evaluated the value of baseline
anti–phospholipase A2 receptor (PLA2R1) antibody titer as a prognostic biomarker in patients with
PLA2R1-associated membranous nephropathy.
Methods: In this cohort study, we included 168 patients (118 men, 50 women) referred to our nephrology
center between February 1995 and November 2016. Mean age was 52  13 years. There were 156 patients
with new-onset disease and 12 patients with a relapse (n ¼ 10) or recent use of immunosuppressive
therapy (n ¼ 2). We measured anti-PLA2R1 titer at baseline and analyzed progression to severe disease
(30% increase of serum creatinine or start of immunosuppressive therapy) as a primary study endpoint
over 60 months.
Results: There was a clear association between anti-PLA2R1 antibody titer and severity of the nephrotic
syndrome. In univariate analysis, anti-PLA2R1 antibody titer was also associated with disease progression.
However, in Cox proportional hazard models that included proteinuria and serum creatinine, anti-PLA2R1
antibody titer was no longer associated with clinical outcome. Results were similar when limiting the
analysis to the patients with new-onset disease.
Conclusion: Our study questions the relevance of single measurement of anti-PLA2R1 antibodies at
baseline as a prognostic biomarker in membranous nephropathy. Future studies are needed to determine
the possible role of sequential measurements of anti-PLA2R1 antibodies as a prognostic biomarker of
disease progression.
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P
rimary membranous nephropathy is the most
common cause of nephrotic syndrome in nondia-
betic Caucasian adults.1 Primary membranous ne-
phropathy (PMN) is considered a renal-limited
autoimmune disease with circulating autoantibodies
against the phospholipase A2 receptor (aPLA2R1ab)
present in 70% to 80% of patients.2,3 After 5 to 10 years
of observation, the natural course of the disease is vari-
able, with 40% to 50% of untreated patients progressing
to end-stage renal disease, whereas the remaining pa-
tients enter into spontaneous remission, sometimes after
years of stable but persistent proteinuria.4,5
Personalized treatment for PMN patients requires
accurate prediction of the disease course at an early
stage, before the start of immunosuppressive treatment.
The best known biomarkers are the magnitude and
duration of proteinuria, and deterioration of kidney
function, reflected by increased serum creatinine or
changes in creatinine clearance.6 These biomarkers
were combined in the validated “Toronto risk score.”6
We recently validated urinary excretion of low
molecular weight proteins including urine alpha-1-
microglobulin as prognostic biomarker.5 Unfortu-
nately, accuracy of current prognostic biomarkers is at
best 80%.5
Recent studies suggested that measurement of
aPLA2R1ab titer may have added value. Indeed, titer of
circulating aPLA2R1ab correlated with clinical disease
activity.7 Additional studies suggested their value as a
prognostic biomarker, because low titers of aPLA2R1ab
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were associatedwith a higher likelihood of remission.8–12
The discovery of aPLA2R1ab associated with different
epitope profiles in patients (due to epitope spreading
and defining "spreaders" and "nonspreaders") also
received considerable interest. Two studies concluded
that epitope spreading at baseline was associated with
clinical outcome.13,14 A more recent study raised
concerns about the use of epitope profile as an inde-
pendent biomarker with added value over aPLA2R1ab
titers.15
Still, the preceding studies have limitations. The
studied cohorts were rather small. Moreover, remission
and renal progression rates were sometimes evaluated
in a mixed cohort of treated and untreated patients.
When using biomarkers, it is important that the study
protocols define the specific use of a biomarker. A
recent Food and Drug Administration guidance docu-
ment distinguishes between prognostic biomarkers
(i.e., biomarkers that allow the selection of patients at
risk for severe disease progression), and predictive
biomarkers that are used to determine the effectiveness
of treatment.16 Thus, it remains unclear whether the
measurement of aPLA2R1ab titers or epitope spreading
is of prognostic value (predicting the clinical evolution
during the natural course of disease in untreated pa-
tients) or of predictive value (predicting response to
immunosuppressive therapy).
For the first time, this study evaluated the prog-
nostic value of aPLA2R1ab titers at baseline next to the
traditional biomarkers (proteinuria, serum creatinine)




Since 1995, patients with PMN referred to our hospital
were evaluated in a standardized way.17 Written
informed consent was obtained and the study was
performed in accordance to the Declaration of Helsinki.
Serum samples were collected and stored at 80C. For
this study, we included patients with PMN and
nephrotic range proteinuria (urine protein-creatinine
ratio [UPCR] $ 3 g/10 mmol in 24-hour urine), with
preserved renal function (serum creatinine level below
135 mmol/l). Secondary causes of MN were excluded
according to our standard policy.17 To evaluate the role
of aPLA2R1ab titers and epitope spreading as a
biomarker of prognosis, we selected all patients who
were identified as positive for aPLA2R1ab, based on
our in-house IgG4 anti-PLA2R1 enzyme-linked immu-
nosorbent assay (ELISA).13
All patients were treated to decrease blood pressure
(target value 130/80 mm Hg), primarily by using
angiotensin-converting-enzyme inhibitors/angiotensin
receptor blockers (ACEi/ARBs). Anticoagulant drugs
were advised when serum albumin levels (immunone-
phelometric assay) dropped below 20 g/l. Patients were
treated according to our restrictive treatment strat-
egy.18 Thus, patients were followed at the outpatient
clinic, while waiting for spontaneous remission.
Immunosuppressive therapy (oral cyclophosphamide
1.5 mg/kg daily in combination with prednisolone
during 6–12 months in most patients) was only pre-
scribed to patients with an increase in serum creatinine
level$30% or patients with (complications of) a severe
disabling nephrotic syndrome.
Definitions and Calculations
To correct for inappropriate 24-hour urine collection,
proteinuria was expressed as UPCRs (UPCR in grams
per 10 mmol of creatinine). In the patient population,
the average creatinine output is 12 mmol/d. Therefore,
we choose 3 g/10 mmol creatinine, which equals 3.5 g/d,
which is used in the definition of remission according
to the Kidney Disease: Improving Global Outcomes
guideline.19 Nephrotic syndrome was defined as UPCR
>3 g/10 mmol/l and serum albumin <30 g/l. Complete
remission was defined as UPCR #0.2 g/10 mmol
creatinine with stable kidney function, and partial
remission was defined as UPCR <3 g/10 mmol creati-
nine with a reduction of at least 50% from baseline and
stable kidney function (# 30% increase of serum
creatinine level from baseline). Achieving spontaneous
remission includes both partial and complete remis-
sion. Time from biopsy was calculated as the time
between kidney biopsy and the first standardized
evaluation in our center.18 Follow-up duration was
calculated from this first standardized evaluation
onward.
Clinical Outcome
Patients were followed at regular intervals according to
local practice. Progression to severe disease was
considered as the primary study endpoint. Patients
with progressive disease (referred to as progressors)
were defined as those requiring immunosuppressive
therapy because of an increase of serum creatinine level
>30% from baseline or severe persistent nephrotic
syndrome. Spontaneous remission was defined as
remission occurring while on conservative therapy
only. For this analysis, patients were censored at the
time they reached the endpoint. The endpoint was
defined only after repeated confirmatory measure-
ments. We investigated a range of prediction horizons
up to 60 months. We limited to 60 months, because we
have shown that >95 % of patients have reached an
endpoint within 5 years after disease onset.18
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Anti-PLA2R1 Antibody Assays
Stored serum samples were retrieved from the Radboud
biobank20 and assessed for aPLA2R1ab titer. Patients
were considered aPLA2R1ab positive if aPLA2R1abs
were positive in our in-house IgG4 anti-PLA2R1
ELISA,13 which was more sensitive than the stan-
dardized commercial ELISA. Titers for anti-PLA2R1ab
were quantified with the standardized commercial
ELISA (Euroimmun, Lübeck, Germany).21 Epitope
spreading defined by positivity for autoantibodies
targeting specific epitopes in the CysR, CTLD1, or
CTLD7 domains were measured by HA-capture ELISA
on 96-well plates coated with CysR-HA, CTLD1-HA,
CTLD7-HA single domains or mock medium from
HEK293-transfected cells as previously described.13
Anti-PLA2R1ab Level and Prognosis in the
Conservative Treatment Arm of the GEMRITUX
Trial
We confirmed our findings in 26 patients with
PLA2R1-associated MN, included in the control arm of
the GEMRITUX clinical trial. Details of patients’ in-
clusion and characteristics have been published.22 Of
the original study, 26 of 38 (68%) patients could be
included, because not all patients gave informed con-
sent for data sharing.
Statistical Analyses
Data are presented as frequency (percentage), mean
(SD), or median (interquartile ranges [IQR]) when
appropriate. T-test, Mann-Whitney U test, and c2 test
were used for comparisons between and within groups.
There were very few missing values in the variables
of interest, therefore we performed a complete case
analysis without imputation. First, we fitted a univar-
iate generalized additive model based on the Cox pro-
portional hazards model and plotted the predicted
values to visualize the dose-response relationship be-
tween predictors and the respective clinical outcomes.
Based on these plots, we took the natural log for
aPLA2R1ab titers. In the Cox proportional hazard
model, we included serum creatinine and UPCR in a
reference model. Next, we added baseline aPLA2R1ab
and/or epitope spreading in the following models.
Subsequently, we analyzed different cutoff values for
the independent prognostic factors and calculated
sensitivity, specificity, and accuracy for predicting the
outcome of progression. If a patient achieved sponta-
neous remission, patients were censored from that
moment on for the outcome of progression. Accuracy
was calculated as the number of correctly classified
patients (true positives and true negatives, divided by
the total number of patients).
We determined model fit using the pseudo R2. The
discriminative ability of the model was determined by
taking the area under the receiver operating charac-
teristic curve at follow-up times of 6, 12, 18, 24, 36, and
60 months. The calibration between predicted and
observed risk was assessed at these time points as well
as using calibration plots.
Analyses were performed with SPSS version 25 (IBM
Corp., Armonk, NY) and R with the RStudio shell (R
Version 3.5.1, RStudio version 1.1463), and packages
foreign_0.8–70, dplyr_0.8.0.1, ggplot2_3.1.1, grid-
Exrta_2.3, tableone_0.10.0, mgcv_1.8–24, crrstep_
2015–2.1, survival_2.42–3, riskRegression_2019.01.29
and their dependencies. Differences were considered
significant with P < 0.05.
RESULTS
In the period from February 1995 to November 2016,
1135 patients with PMN were seen at our outpatient
clinic. Of these, 599 patients fulfilled the inclusion
criteria and of 247 patients samples were available in
our biobank (Figure 1). From these 247 patients, 168
were aPLA2R1ab positive and finally included in this
study. Of these, 64 patients were included in a previ-





- aPLA2Rab IgG4 negative: 56 (6 
patients aTHSD7A positive)
- No baseline sample available: 7
- No follow-up available: 13
- Relapse and/or previous
immunosuppressive therapy: 12
- Immunosuppressive therapy
because of other autoimmune
disease: 2




















- sCreatinine > 135 µmol/l: 299 
- Proteinuria < 3 grams/10 
mmol: 237
Figure 1. Flowchart of patients’ inclusion. MN, membranous
nephropathy.
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newly diagnosed. Twelve patients were evaluated with
a documented relapse (n ¼ 10), or recent use of
immunosuppressive therapy (n ¼ 2). In our initial
analysis we included all 168 patients. We observed
lower aPLA2R1ab levels in these 12 patients (median
aPLA2R1ab titer 45 RU/ml [IQR 12–86 RU/ml]).
Therefore, a second analysis including only patients
with incident disease was done. Results of all 168 pa-
tients are given in Supplementary Appendix Part A
Tables 1-4. The baseline characteristics of the 156
incident patients are described in Table 1. The interval
between kidney biopsy and the standardized evalua-
tion at our center was 2.3 months. At the time of
evaluation, 85% of patients were on ACEi/ARBs. All
Table 1. Risk characteristics of patients with new-onset primary membranous nephropathy according to outcome during the 60-month
observation period




n [ 51 Persistent NS n [ 4a P value
Age (y) 52  13 53  13 51  13 45 [40–61] 0.470
Gender (M/F, % M) 112/44 (72) 71/30 (70) 37/14 (73) 4/0 (100) 0.428
Time from biopsy (mo) b 2.3 [1.2–6.6] 2.2 [1.1–5.5] 2.8 [1.4–7.8] 9.9 [0.9–31] 0.198
Serum creatinine (mmol/l) 92  18 96  19 86  15 94 [69–116] 0.009
Serum albumin (g/l) 21  5 19  5 23  5 24 [21–28] 0.000
Serum cholesterol (mmol/l) 6.6 [5.2–8.7] 7.3 [5.5–9.3] 5.8 [5.2–7.1] 6.0 [5.0–13.0] 0.005
Serum IgG (g/l) 4.4 [3.1–5.4] 3.8 [2.9–5.1] 5.0 [4.0–6.1] 4.0 [4.0–8.0] 0.005
Proteinuria (g/10 mmol) 7.2 [5.7–10.9] 9.4 [6.4–11.6] 6.0 [4.7–7.9] 5.5 [4.0–7.0] 0.000
aPLA2R1ab titer Euroimmun (RU/ml) 110 [47–244] 152 [70–312] 50 [33–128] 217 [39–829] 0.000
Spreaders, n (%) 112 (72) 81 (79) 29 (57) 2 (50) 0.014
Urinary b2m (ng/min) 981 [284–3808] 2257 [481–8626] 315 [168–692] 348 [126–8743] 0.000
Urinary a1m (mg/min) 46 [27–83] 63 [41–105] 29 [20–43] 13 [8–57] 0.000
IgG excretion (mg/24 h) 306 [165–504] 394 [237–600] 185 [108–314] 90 [60–309] 0.000
MAP (mm Hg) 93 [85–102] 93 [87–102] 90 [83–101] 95 [91–105] 0.299
ACEi/ARB use (%) 105/124 (85) 62/80 (78) 42/43 (98) 4/4 (100) 0.002
a1m, alpha-1-microglobulin; ACEi/ARB, angiotensin-converting-enzyme inhibitor/angiotensin receptor blockers; MAP, mean arterial blood pressure; NS, nephrotic syndrome.
aIn patients with persisting proteinuria (n ¼ 4), values are given as median [range].
bTime from biopsy ¼ interval between biopsy and standardized measurement in our hospital.
Values are given as mean  SD, median [IQR], number (percentage).
Figure 2. The cumulative incidence of progression (red line) and spontaneous remission (blue line). The number of patients at risk of pro-
gression is presented on the X-axis.
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patients were followed until the endpoint, or a
maximum of 60 months. During the 60 months of
follow-up, 152 patients reached the study endpoint,
that is, disease progression (n ¼ 101, 65%) or sponta-
neous remission (n ¼ 51, 33%). Four patients (2%) had
persisting proteinuria. Progression occurred within a
median of 5 months [IQR 2–11] after initial evaluation.
Spontaneous remission occurred within a median of 18
months [IQR 11–28] after initial evaluation. Complete
spontaneous remission was achieved in 21 patients
(40% of all remissions) within a median of 51 months
[IQR 35–77] after initial evaluation. The cumulative
incidence of progression versus spontaneous remission
is depicted in Figure 2. We compared patients who
progressed with those developing spontaneous remis-
sion or with persisting proteinuria (Table 1). Age,
gender, and time from biopsy were not different be-
tween groups. Progressors had higher serum creati-
nine, a more severe nephrotic syndrome, higher levels
of urinary low molecular weight proteins, higher titers
of aPLA2R1ab, were more often “spreaders,” and used
ACEi/ARB therapy less often.
Associations of aPLA2R1ab Titer and Epitope
Spreading With Clinical Outcome
Baseline characteristics according to aPLA2R1ab tertiles
are presented in Table 2. Age, gender, and interval
between biopsy and standardized measurement were
not different between groups. Patients in the highest
tertile of aPLA2R1ab had a more severe nephrotic
syndrome and a higher level of urinary low molecular
weight proteins. There was a clear association between
aPLA2R1ab titers and the prevalence of epitope
spreading. In this cohort, all patients with aPLA2R1ab
titer >176 RU/ml were spreaders. Progression was
observed in 23 (44%), 37 (71%), and 43 (83%) of pa-
tients in the first, second, and third tertiles, respec-
tively. The median time to progression was 4 months
[IQR: 2–12], 6 months [IQR 2–13], and 5 months [IQR 2–
10], respectively. Baseline characteristics of patients
according to epitope spreading (spreaders versus non-
spreaders) are given in Supplementary Appendix Part
B Table S1. Progression was less frequent in non-
spreaders (48%) than spreaders (73%).
Cox Proportional Hazard Models
Hazard ratios and C-statistics are given for the risk
prediction models using a time horizon of 36 months in
Table 3. Full data for all evaluated time horizons are
given in Supplementary Appendix Part B Table S2.
Proteinuria and serum creatinine were clear prognostic
biomarkers in a model using only these 2 biomarkers
(model 1, area under the curve [AUC] 0.715). Anti-
PLA2R1ab did not improve the model (model 2 AUC
0.708). Epitope spreading as an additional single vari-
able slightly improved model 1 (model 3 AUC 0.723
Supplementary Appendix Part B Table S3). Calibration
Table 2. Baseline characteristics of patients according to tertiles of aPLA2R1ab
n [ 156
First tertilea
8--59 RU/mL n [ 52
Second tertile
63--178 RU/mL n [ 52
Third tertile
182--1239 RU/mL n [ 52 P value
Age (y) 50  11 53  15 54  12 0.564
Gender (M/F, % M) 39/13 (75) 38/14 (73) 35/17 (67) 0.663
Time from biopsy (months) 3.1 [1.4–8.7] 2.0 [1.1–5.9] 2.3 [1.2–6.6] 0.292
Serum creatinine (mmol/l) 90 [81–105] 91 [82–105] 95 [78–111] 0.208
Serum albumin (g/l) 24 [18–28] 20 [17–24] 19 [15–22] 0.063
Serum cholesterol (mmol/l) 6.3 [5.0–8.2] 6.8 [5.4–8.3] 6.7 [5.4–9.7] 0.584
Serum IgG (g/l) 4.9 [3.8–5.8] 3.9 [3.1–5.0] 4.2 [3.0–5.1] 0.199
Proteinuria (g/10 mmol) 6.0 [4.5–8.7] 8.0 [6.2–11.0] 9.0 [6.0–11.2] 0.003
Urinary b2m (ng/min) 547 [242–2298] 832 [202–3569] 2112 [382–8385] 0.037
Urinary a1m (mg/min) 42 [25–68] 49 [24–95] 58 [37–98] 0.070
IgG excretion (mg/24 h) 265 [122–391] 306 [120–557] 383 [229–591] 0.009
MAP (mm Hg) 93 [85–100] 93 [86–104] 92 [85–104] 0.886
ACEi/ARB use, n (%) 39/41 (95) 29/41 (71) 37/42 (88) 0.063
Spreaders, n (%) 29 (56) 37 (71) 46 (89) 0.001
a1m, alpha-1-microglobulin; ACEi/ARB, angiotensin-converting-enzyme inhibitor/angiotensin receptor blockers; MAP, mean arterial blood pressure.
aThere were 3 patients with an Euroimmun aPLA2Rab titer < 14 Ru/ml with a positive results in our homemade IG4 aPLA2Rab assay.
Values are given as mean  SD, median [IQR].
Table 3. Cox regression analysis: models with known biomarkers for
the prediction of progression
AUC 36 mo HR 95% CI
Model 1
Screat 0.715 1.019 1.007–1.031
UPCR 1.185 1.116–1.258
Model 2
Screat 0.708 1.018 1.006–1.030
UPCR 1.175 1.105–1.249
Log.aPLA2R1ab 1.373 0.897–2.102
AUC, area under the curve/C-statistic; CI, confidence interval; HR, hazard ratio;
Log.aPLA2R1ab, natural log of anti-PLA2R antibodies; Screat, serum creatinine; UPCR¼
protein-creatinine ratio in 24-hours urine.
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plots are given in the supplementary appendix
(Supplementary Appendix Part B Figure S1).
Individualized Risk Prediction: Test Characteris-
tics of Prognostic Markers
Accuracy of prediction models is limited. The use of a
model is not easy in clinical practice. To discuss man-
agement strategies with the individual patient, we
provide the test characteristics of aPLA2R1ab for the
prediction of progression (Supplementary Appendix
Part B Table S4a). This table provides information
that can be used to discuss prognosis with the indi-
vidual patient based on the results of the biomarker
measurement in that patient.
Subanalysis in Patients With Normal Serum
Creatinine Levels
For this subanalysis, we excluded all female patients
with a serum creatinine level ˃90 mmol/l and all male
patients with a serum creatinine level ˃110 mmol/l. We
also excluded patients who received immunosuppres-
sive therapy within 6 months after standardized mea-
surement. Of the original 156 patients, 85 patients
remained for this analysis (Table 4). The number of
progressors according to outcome based on total
follow-up duration was 39 (46 %) with no differences
between women and men. In univariate analysis
aPLA2R1ab titers were numerically higher in patients
with progressive disease, although not significant (P ¼
0.066). Also in this subgroup analysis, aPLA2R1ab
levels did not improve a model incorporating serum
creatinine and proteinuria. The limited value of
aPLA2R1ab for individual patient care is shown in
Figure 3, illustrating the wide overlap in aPLA2R1ab
titers between progressors and nonprogressors. The
test characteristics of aPLA2R1ab for the prediction
of progression in this cohort is presented in
Supplementary Appendix Part B Table S4b.
Anti-PLA2R1ab Level and Prognosis in the
Conservative Treatment Arm of the GEMRITUX
Trial
In our cohort, baseline aPLA2R1ab titer was not inde-
pendently associated with disease progression, ques-
tioning the value of aPLA2Rab titers as a prognostic
biomarker. To confirm our findings, we analyzed the
clinical outcome of 26 patients with PLA2R1-associated
MN, randomly included in the control arm (with only
conservative treatment) of the GEMRITUX clinical
trial.22 The baseline characteristics of these patients are
given in Table 5. Remarkably, aPLA2R1ab titers in this







n [ 46 P value
Age (y) 50  12 51  11 50  13 0.674
Gender (M/F, % M) 65/20 (77) 30/9 (77) 35/11 (76) 1.000
Time from biopsy (mo) 2.1 [1.3–5.9] 2.1 [1.4–3.0] 2.1 [1.3–7.6] 0.892
Serum creatinine (mmol/l) 83  13 85  14 82  12 0.463
Serum albumin (g/l) 22  5 20  5 23  5 0.038
Serum cholesterol (mmol/l) 6.9 [5.3–8.9] 8.0 [6.2–9.5] 6.0 [5.2–7.5] 0.004
Serum IgG (g/l) 4.8 [3.4–5.6] 4.2 [3.0–5.3] 5.0 [4.0–6.2] 0.101
Proteinuria (g/10 mmol) 6.4 [4.9–9.3] 7.2 [5.6–11.0] 5.9 [4.6–7.7] 0.332
aPLA2R1ab titer (RU/ml) 95 [43–180] 125 [69–300] 49 [33–131] 0.066
Spreaders, n (%) 52/33 (61) 27 (69) 25 (54) 0.186
Urinary b2m (ng/min) 390 [178–1235] 550 [274–1686] 277 [154–553] 0.035
Urinary a1m (mg/min) 32 [22–50] 43 [29–67] 28 [14–42] 0.023
IgG excretion (mg/24 h) 203 [120–363] 261 [156–404] 184 [97–312] 0.049
MAP (mm Hg) 93 [84–103] 96 [85–105] 90 [83–101] 0.125
ACEi/ARB use (%) 60/70 (86) 23/32 (72) 37/38 (97) 0.010
a1m, alpha-1-microglobulin; ACEi/ARB, angiotensin-converting-enzyme inhibitor/angiotensin receptor blockers; MAP, mean arterial blood pressure.
Values are given as mean  SD, median [IQR], number (percentage).
Figure 3. aPLA2R1ab levels at baseline of patients with normal
serum creatinine with progression (n ¼ 39) and or spontaneous
remission (n ¼ 46).
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cohort were higher than aPLA2R1ab titers in our study
cohort. During 24 months of follow-up, 14 patients
were identified as progressors and/or received addi-
tional immunosuppressive therapy, whereas 12 pa-
tients were identified as nonprogressors, achieving
spontaneous remission. Although the median
aPLA2R1ab titer at the initiation of the clinical trial was
higher in progressors, the difference did not reach
significance. The aPLA2R1ab titers in progressors
versus nonprogressors are illustrated in Supplementary
Appendix Part B Figure S2. In Cox regression analysis,
aPLA2R1ab titers below and above the median were
not independently associated with disease progression
(data not shown).
DISCUSSION
Optimal, personalized management and treatment of
patients with PMN require accurate risk prediction.
We previously showed that urinary excretion of low
molecular weight proteins could be used as a prog-
nostic biomarker, with accuracy comparable to models
that included the magnitude and duration of protein-
uria.5,6 Still, these models lacked sufficient accuracy,
with an AUC of approximately 0.80. The discovery of
aPLA2R1ab, which are present in more than 70% of
patients with PMN and are likely involved in patho-
genesis, offers a new hope for better risk prediction.
Indeed, high titers of aPLA2R1ab have been associated
with reduced likelihood of spontaneous remission7–10
and poor clinical outcome.11,23,24 Two studies further
suggested that analysis of epitope-specific aPLA2R1ab
could improve risk prediction,13,14 although the added
value over aPLA2R1ab titer was debated in a recent
study.15
Literature data on biomarkers for patients with PMN
must be interpreted with caution. Most studies were of
limited size, and included patients treated and un-
treated with immunosuppressants. The Food and Drug
Administration defines biomarkers and use the BEST
(Biomarkers, EndpointS, and other Tools) glossary to
define biomarker categories.16 With respect to risk
prediction, it is important to differentiate between
prognostic and predictive biomarkers. A prognostic
biomarker is used to identify the likelihood of a clinical
event in patients with the disease. Such a biomarker
thus predicts the natural course of the disease. In
contrast, a predictive biomarker is used to identify
individuals who are more or less likely to respond to
drug therapy. Distinguishing between prognostic and
predictive biomarkers can be difficult. Prognostic bio-
markers can be identified from observational data in a
natural disease cohort of untreated patients. To identify
a predictive biomarker, there should be a comparison
between the outcome in treated patients versus con-
trols, as evaluated in clinical trials, both in patients
with and without the biomarker. Of note, it is impos-
sible to distinguish between prognostic and predictive
biomarkers when only treated patients are included in
a study.16
Obviously, the study of prognostic biomarkers is
relevant only for patients with equivocal outcome. The
inclusion of patients who are at no risk for a particular
outcome weakens the study. Patients with non-
nephrotic PMN have good clinical outcome25 and
should be excluded from studies that search for prog-
nostic biomarkers. We studied the role of aPLA2R1ab
titers as prognostic biomarkers in patients with PMN.
The initial analysis included patients with PMN and
new-onset or relapsing nephrotic syndrome. However,
we observed lower aPLA2R1ab levels in patients with
relapsing disease. Therefore, a second analysis
including only patients with incident disease was done.
Results of the analysis were similar. Immunosuppres-
sive therapy during follow-up was advised for patients
with evidence of deteriorating kidney function or pa-
tients with severe and/or complicated nephrotic syn-
drome, who are considered at high risk for progression.
We noted clear associations between aPLA2R1ab titers,
epitope spreading, and disease severity as reflected by
the magnitude of proteinuria, serum albumin levels,
and urine excretion of IgG. A Cox proportional hazard
model that included UPCR and serum creatinine had
reasonable predictive value. This was expected, as
proteinuria and estimated glomerular filtration rate are
components of the well-known Toronto risk score.6 In
univariate analysis, higher titers of aPLA2R1ab were
associated with disease progression. However, in the
proportional hazard model including UPCR and serum
creatinine, aPLA2R1ab titers did not improve risk
prediction. To confirm our findings, we evaluated the
prognostic value of aPLA2R1ab on the risk of disease
worsening of patients included in the control arm of
the GEMRITUX clinical trial. The GEMRITUX data
were similar to those observed in our cohort, with
baseline aPLA2R1ab titers having no accurate prog-
nostic value.
Table 5. Baseline characteristics of patients in the conservative
treatment group of the GEMRITUX trial
Progressors n [ 14 Nonprogressors n [ 12 P value
Age (y) 61 [41–69] 59 [45–63] 1.000
Sex (M/F, % M) 9/5 (64) 8/4 (67) 1.000
aPLA2R1ab titer (RU/ml) 405 [38–853] 132 [23–465] 0.238
Proteinuria (g/10 mmol) 7.9 [6.4–10.4] 7.1 [3.9–8.9] 0.695
Serum Albumin (g/l) 24 [20–26] 21 [16–23] 0.238
Serum Creatinine (mmol/l) 94 [76–137] 92 [79–109] 0.713
Values are given as median [IQR].
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Our findings showing that aPLA2R1ab titer has no
added value over traditional biomarkers to predict
progression seem contradictory to recent studies that
also evaluated aPLA2R1ab as a prognostic biomarker.
In a previous study, we showed that patients in the
highest tertile of aPLA2R1ab were less likely to develop
spontaneous remission.7 However, accuracy was not
reported and multivariable analysis was not done.
Other recent studies concluded that patients with low
baseline aPLA2R1ab titers were more likely to develop
spontaneous remission.9,10 However, these studies have
methodological flaws, because they included patients
without detectable aPLA2R1ab, and patients without
nephrotic syndrome or patients with established renal
insufficiency.
In other studies that evaluated the association be-
tween aPLA2R1ab and outcome, there was no distinc-
tion between aPLA2R1ab as a prognostic and predictive
biomarker. All recent studies included patients treated
with and without immunosuppressive therapy, and the
studies did not report clinical outcomes in the 4 sub-
groups (treated vs. untreated with and without
biomarker). In the largest studies, 85% to 100% of pa-
tients were treated.11,26 The study of Mahmud et al.,26 is
an example of a predictive biomarker study. The
endpoint in this study, doubling of serum creatinine, or
development of end-stage renal disease, was evaluated in
treated and untreated patients. In fact, in this study,
85% of nephrotic patients were treated with immuno-
suppressive therapy; treatment was started on average
within 3 months after disease onset, treated patients had
higher aPLA2R1ab titers, and were more likely to reach
a study endpoint. Thus, this study can be used only to
evaluate aPLA2R1ab levels as predictive biomarker (e.g.,
predicting the efficacy of treatment). Our and these
latter studies suggest that aPLA2R1ab titers are more
likely to have predictive than prognostic value.
In this study, we also evaluated the added value of
“epitope spreading” and our data suggest that epitope
spreading might have limited added value over
aPLA2R1ab titers.
For clinical practice, it is important to realize that all
biomarkers lack accuracy. In discussing treatment
options with patients, false negative or false positive
rates of 20% to 25% are relevant. Supplementary
Appendix Part B Table S4 provides important infor-
mation for clinical practice. Nephrologists can use this
table to discuss individualized prognosis with their
individual patient, based on the results of the available
assays.
Our study has important limitations. We only eval-
uated the role of aPLA2R1ab titers at baseline as a
prognostic biomarker. It is possible that measurement
of changes in aPLA2R1ab has prognostic value.
Moreover, measurement of aPLA2R1ab titers may allow
to predict response to immunosuppressive therapy.
Another limitation is the inclusion of patients with
slightly reduced kidney function. Admittedly, this
might have favored serum creatinine as a prognostic
biomarker. In a subanalysis that included only patients
with a normal kidney function, a wide overlap of
aPLA2R1ab levels between progressors and non-
progressors was observed. Also, in a multivariate
model including UPCR and serum creatinine,
aPLA2R1ab titers did not improve risk prediction.
Another limitation is the definition of disease pro-
gression. Doubling of serum creatinine and/or end-stage
kidney disease are valid renal endpoints. However, we
feel that in the current era it can no longer be accepted
to delay immunosuppressive therapy in patients with
PMN at high risk for disease progression or complica-
tions. Obviously, because the start of immunosuppres-
sive therapy is mostly governed by severity of nephrotic
syndrome or kidney dysfunction, its use as study
endpoint is debatable and open to confounding.
Therefore, the question is if start of immunosuppressive
therapy equals progressive disease. We suggest that in
our study start of immunosuppressive therapy correctly
identified the high-risk patients. We can provide some
arguments: First, start of immunosuppressive therapy
was not at random but dictated by laboratory markers of
kidney disfunction. In 62% of patients, treatment was
started after serum creatinine had increased >30% or
when estimated glomerular filtration rate was <60 ml/
min per 1.73 m2. Second, our treatment was restrictive;
35% of patients did not receive immunosuppressive
therapy. This is in agreement with reported spontaneous
remission rates of 30% to 40 %, suggesting that our
clinical decision making was quite reasonable. Third,
our treatment was often delayed, with treatment started
>6 months after biopsy in 74% of patients. Last, the
decision to start therapy was done without knowledge
of aPLA2R1ab levels.
One might also debate the endpoint of “non-
progressor.” In this respect, a lack of follow-up in
patients who developed a spontaneous remission could
pose a problem. If these patients all had a relapse, and
would have received immunosuppressive therapy at
the time of relapse, there would be no value of pre-
dicting prognosis. Therefore, we have gathered follow-
up data of patients with spontaneous remission. There
were 51 patients who developed spontaneous remis-
sion, with a median duration of follow-up after
remission of 3.5 [1–8] years. During this period of
follow-up, only 2 patients (4%) received immunosup-
pressive therapy.
We have confirmed our results with data from the
control arm of the GEMRITUX clinical trial. Similar to
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data obtained from the original cohort, aPLA2R1ab ti-
ters had no prognostic value in the GEMRITUX pa-
tients. A limitation of this validation is obviously the
small number of patients. However, these data are of
clinical relevance in the individual patient.
Improved outcome prediction will require a more
complex model that would include repeated measure-
ments of serum creatinine, UPCR, and aPLA2R1ab titer.
Also gender and age should be incorporated into the
model. Larger discovery and validation cohorts are
needed to develop such risk models/calculators.
CONCLUSION
Anti-PLA2R1 antibodies did not improve the risk
prediction in PLA2R1-associated PMN when added as a
single parameter in a model based on UPCR and serum
creatinine.
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